Business
ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering patients and their caregivers to better protect against severe allergic reactions that can lead to anaphylaxis, today announced the appointment of Donn Casale as President, effective June 1, 2026. Richard Lowenthal will continue to lead ARS Pharma as Chief Executive Officer. Mr. Casale is a 25-year biopharmaceutical commercial leader with extensive experience
About this update from Ars Pharmaceuticals, Inc.
[{"type":"image","alt":"ARS Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"ARS Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":117,"url":"https://media.zenfs.com/en/globenewswire.com/48986e4b8db7a2adc13bb417709be92b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JUMnuOEmWEj4BcBK3f2C3g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/48986e4b8db7a2adc13bb417709be92b","width":300,"height":117},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/JUMnuOEmWEj4BcBK3f2C3g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/48986e4b8db7a2adc13bb417709be92b","width":300,"height":117}},"lazy":false},{"type":"text","content":"SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering patients and their caregivers to better protect against severe allergic reactions that can lead to anaphylaxis, today announced the appointment of Donn Casale as President, effective June 1, 2026. Richard Lowenthal will continue to lead ARS Pharma as Chief Executive Officer.","length":413,"tagName":"p"},{"type":"text","content":"Mr. Casale is a 25-year biopharmaceutical commercial leader with extensive experience scaling innovative products in large consumer-driven healthcare markets, including categories where patients seek therapies that help reduce the risk of future serious medical events. As President, Mr. Casale will oversee global commercial operations and growth infrastructure as ARS Pharma prepares for its next phase of expansion, including advancement into chronic spontaneous urticaria (CSU). He will partner closely with the executive leadership team to help drive the company’s next phase of commercial and organizational growth.","length":621,"tagName":"p"},{"type":"text","content":"“We are very pleased to welcome Donn to the ARS team, where he will play a key role in leading our commercial strategy for neffy® (epinephrine nasal spray) and accelerating adoption and sales growth,” said Richard Lowenthal, Co-founder and CEO of ARS Pharma. “Donn has built and led commercial organizations that successfully scaled innovative products in large, patient-driven markets similar to our own. His expertise in retail channel execution a...